Pain Management Therapeutics Market (Therapeutics - Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDS), Opioids, Other Non-narcotic Analgesic, and Antimigraine Agents; Indication - Neuropathic Pain, Fibromyalgia, Arthritic Pain, Chronic Back Pain, Migraine, Post-Operative Pain, and Cancer Pain) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Description

The global pain management therapeutics market for the historical period 2017–2018 and forecast period 2019–2027, high incidence of chronic pain disorders, easy and effective medications, and higher demand of pain management products are projected to drive the global pain management therapeutics market during the forecast period

According to the report, the global pain management therapeutics market was valued at US$ 66.6 Bn in 2018 and is anticipated to expand at a CAGR of 3.7% from 2019 to 2027

Rise in Incidence of Chronic Pain Disorders to Promote Usage of Pain Management Therapeutics: Key Drivers

The number of patients suffering from chronic pain is on a constant rise globally. For instance, according to the World Health Organization (WHO), the U.S. had 50 million people suffering from chronic pain in 2018. Additionally, according to a European Pain Federation, around 80 Mn adults in Europe suffers from chronic pain.

The global increasing incidence rates of cancer further contribute to the rise in demand for pain management therapeutics. This includes pain occurring from cancer therapy as well as from incursion of cancer cells on to bones and other healthy body parts. WHO projections suggest that the global cancer prevalence will increase by around 75% from 2008 to 2030.

Hence, increase in incidence of chronic pain conditions continue to encourage the use of pain management drugs, thereby driving the market.

Easy & Effective Medications and Higher Demand of c Growth

Doctors usually prescribe medicines in the initial stages of pain, followed by other treatment options. Prescription drugs are easy and economical to use at individual level without any ambiguity.

Increased awareness about availability of medications for pain management propels consumption and acceptance of pain management drugs over other treatment options. Hence, high availability, easy access, high awareness, cost effectiveness, and quick relief have made pain management therapeutics more preferable to other treatment options.

According to National Prescription Audit (May 2019), pain treatment was the fourth largest therapy in the U.S., with about 447 million prescriptions after lipid regulators.

However, prescription volume for pain therapy decreased by 4.5% in 2018 as compared to 2017, due to continued implementation of control on volume of dispensing prescriptions for narcotic or opioid pain medicines, thereby reducing the misuse of drugs for non-medical use

Side Effects and Risk of drug abuse with opioids to Hamper Market

The common side effects experienced from long-term usage of pain therapeutics include constipation, drowsiness, and respiratory depression. Commonly used NSAIDs for pain management have high risk of gastrointestinal ulceration or bleeding. COX-2 inhibitors were developed to eliminate this risk; however, these led to other issues such as risk of heart attack and stroke due to prolonged use.

Prescription drug abuse poses a serious threat to the growth of the pain management therapeutics market due to its harmful long term effects. For instance as per National Institute Drug Abuse USA, more than 2 million people in the United States suffer from substance use disorders related to prescription opioid pain relievers.

Global Pain Management Therapeutics Market: Competitive Landscape

This report profiles major players in the global pain management therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global pain management therapeutics market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global pain management therapeutics market are

  • Pfizer Inc.
  • Depomed, Inc.
  • Endo International plc.
  • Purdue Pharma L.P.
  • Mallinckrodt Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca plc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc.

Key Questions Answered in Global Pain Management Therapeutics Market Report

  • What is the scope of growth of product companies in the global pain management therapeutics market?
  • What will be the Y-o-Y growth of the global pain management therapeutics market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global pain management therapeutics market?
  • Will North America continue to be the most profitable market for pain management therapeutics providers?
  • Which factors are anticipated to hamper the growth of the global pain management therapeutics market during the forecast period?
  • Which are the leading companies in the global pain management therapeutics market?

Global Pain Management Therapeutics Market - Segmentation

Therapeutics

  • Anticonvulsants
  • Antidepressants
  • Anesthetics
  • NSAIDS
  • Opioids
  • Oxycodones
  • Hydrocodones
  • Tramadol
  • Others
  • Antimigraine Agents
  • Other Non-narcotic Analgesic
  • Anticonvulsants

Indication

  • Neuropathic Pain
  • Fibromyalgia
  • Arthritic Pain
  • Chronic Back Pain
  • Migraine
  • Post-Operative Pain
  • Cancer Pain

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pain Management Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pain Management Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Chronic Pain Disease Epidemiology, by Region/Major Countries

    5.2. Pipeline Analysis

    5.3. Brand Analysis

    5.4. Most Types of Body Pain Location Globally and Cut By Gender and Parents

    5.5. Most Types of Head Pain Location Globally and Cut By Gender and Parents

6. Global Pain Management Therapeutics Market Analysis and Forecast, by Type

7. Global Pain Management Therapeutics  Market Analysis, By Therapeutics

    7.1. Introduction 

    7.2. Global Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    7.3. Global Pain Management Therapeutics Market Forecast, by Therapeutics

        7.3.1. Anticonvulsants

        7.3.2. Antidepressants

        7.3.3. Anesthetics

        7.3.4. NSAIDS

        7.3.5. Opioids

            7.3.5.1. Oxycodones

            7.3.5.2. Hydrocodones

            7.3.5.3. Tramadol

            7.3.5.4. Others

        7.3.6. Antimigraine Agents

        7.3.7. Other Non-narcotic Analgesic

    7.4. Global Pain Management Therapeutics Market Analysis, by Therapeutics

8. Global Pain Management Therapeutics  Market Analysis, By Indication

    8.1. Introduction 

    8.2. Global Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    8.3. Global Pain Management Therapeutics Market Forecast, by Indication

        8.3.1. Neuropathic Pain 

        8.3.2. Fibromyalgia 

        8.3.3. Arthritic Pain 

        8.3.4. Chronic Back Pain 

        8.3.5. Migraine 

        8.3.6. Post-Operative Pain 

        8.3.7. Cancer Pain 

    8.4. Global Pain Management Therapeutics Market Analysis, by Indication 

9. Global Pain Management Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Pain Management Therapeutics Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global Pain Management Therapeutics Market Attractiveness, by Region

10. North America Pain Management Therapeutics Market Analysis

    10.1. Key Findings

    10.2. North America Pain Management Therapeutics Market Overview

    10.3. North America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Country

    10.4. North America Pain Management Therapeutics Market Forecast, by Country

        10.4.1. U.S.

        10.4.2. Canada

    10.5. North America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    10.6. North America Pain Management Therapeutics Market Forecast, by Therapeutics

        10.6.1. Anticonvulsants

        10.6.2. Antidepressants

        10.6.3. Anesthetics

        10.6.4. NSAIDS

        10.6.5. Opioids

            10.6.5.1. Oxycodones

            10.6.5.2. Hydrocodones

            10.6.5.3. Tramadol

            10.6.5.4. Others

        10.6.6. Antimigraine Agents

        10.6.7. Other Non-narcotic Analgesic

    10.7. North America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    10.8. North America Pain Management Therapeutics Market Forecast, by Indication

        10.8.1. Neuropathic Pain 

        10.8.2. Fibromyalgia 

        10.8.3. Arthritic Pain 

        10.8.4. Chronic Back Pain 

        10.8.5. Migraine 

        10.8.6. Post-Operative Pain 

        10.8.7. Cancer Pain

11. Europe Pain Management Therapeutics Market Analysis

    11.1. Key Findings

    11.2. Europe Pain Management Therapeutics Market Overview

    11.3. Europe Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Country/Sub-region

    11.4. Europe Pain Management Therapeutics Market Forecast, by Country/Sub-region

        11.4.1. Germany

        11.4.2. U.K.

        11.4.3. France

        11.4.4. Italy

        11.4.5. Spain

        11.4.6. Rest of Europe

    11.5. Europe Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    11.6. Europe Pain Management Therapeutics Market Forecast, by Therapeutics

        11.6.1. Anticonvulsants

        11.6.2. Antidepressants

        11.6.3. Anesthetics

        11.6.4. NSAIDS

        11.6.5. Opioids

            11.6.5.1. Oxycodones

            11.6.5.2. Hydrocodones

            11.6.5.3. Tramadol

            11.6.5.4. Others

        11.6.6. Antimigraine Agents

        11.6.7. Other Non-narcotic Analgesic

    11.7. Europe Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    11.8. Europe Pain Management Therapeutics Market Forecast, by Indication

        11.8.1. Neuropathic Pain 

        11.8.2. Fibromyalgia 

        11.8.3. Arthritic Pain 

        11.8.4. Chronic Back Pain 

        11.8.5. Migraine 

        11.8.6. Post-Operative Pain 

        11.8.7. Cancer Pain 

12. Asia Pacific Pain Management Therapeutics Market Analysis

    12.1. Key Findings

    12.2. Asia Pacific Pain Management Therapeutics Market Overview

    12.3. Asia Pacific Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Country/Sub-region

    12.4. Asia Pacific Pain Management Therapeutics Market Forecast, by Country/Sub-region

        12.4.1. China

        12.4.2. Japan

        12.4.3. India

        12.4.4. Australia & New Zealand

        12.4.5. Rest of Asia Pacific

    12.5. Asia Pacific Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    12.6. Asia Pacific Pain Management Therapeutics Market Forecast, by Therapeutics

        12.6.1. Anticonvulsants

        12.6.2. Antidepressants

        12.6.3. Anesthetics

        12.6.4. NSAIDS

        12.6.5. Opioids

            12.6.5.1. Oxycodones

            12.6.5.2. Hydrocodones

            12.6.5.3. Tramadol

            12.6.5.4. Others

        12.6.6. Antimigraine Agents

        12.6.7. Other Non-narcotic Analgesic

    12.7. Asia Pacific Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    12.8. Asia Pacific Pain Management Therapeutics Market Forecast, by Indication

        12.8.1. Neuropathic Pain 

        12.8.2. Fibromyalgia 

        12.8.3. Arthritic Pain 

        12.8.4. Chronic Back Pain 

        12.8.5. Migraine 

        12.8.6. Post-Operative Pain 

        12.8.7. Cancer Pain

13. Latin America Pain Management Therapeutics Market Analysis

    13.1. Key Findings

    13.2. Latin America Pain Management Therapeutics Market Overview

    13.3. Latin America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Country/Sub-region

    13.4. Latin America Pain Management Therapeutics Market Forecast, by Country/Sub-region

        13.4.1. Brazil

        13.4.2. Mexico

        13.4.3. Rest of Latin America

    13.5. Latin America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    13.6. Latin America Pain Management Therapeutics Market Forecast, by Therapeutics

        13.6.1. Anticonvulsants

        13.6.2. Antidepressants

        13.6.3. Anesthetics

        13.6.4. NSAIDS

        13.6.5. Opioids

            13.6.5.1. Oxycodones

            13.6.5.2. Hydrocodones

            13.6.5.3. Tramadol

            13.6.5.4. Others

        13.6.6. Antimigraine Agents

        13.6.7. Other Non-narcotic Analgesic

    13.7. Latin America Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    13.8. Latin America Pain Management Therapeutics Market Forecast, by Indication

        13.8.1. Neuropathic Pain 

        13.8.2. Fibromyalgia 

        13.8.3. Arthritic Pain 

        13.8.4. Chronic Back Pain 

        13.8.5. Migraine 

        13.8.6. Post-Operative Pain 

        13.8.7. Cancer Pain

14. Middle East & Africa Pain Management Therapeutics Market Analysis

    14.1. Key Findings

    14.2. Middle East & Africa Pain Management Therapeutics Market Overview

    14.3. Middle East & Africa Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Country/Sub-region

    14.4. Middle East & Africa Pain Management Therapeutics Market Forecast, by Country/Sub-region

        14.4.1. GCC Countries

        14.4.2. South Africa

        14.4.3. Rest of Middle East & Africa

    14.5. Middle East & Africa Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Therapeutics

    14.6. Middle East & Africa Pain Management Therapeutics Market Forecast, by Therapeutics

        14.6.1. Anticonvulsants

        14.6.2. Antidepressants

        14.6.3. Anesthetics

        14.6.4. NSAIDS

        14.6.5. Opioids

            14.6.5.1. Oxycodones

            14.6.5.2. Hydrocodones

            14.6.5.3. Tramadol

            14.6.5.4. Others

        14.6.6. Antimigraine Agents

        14.6.7. Other Non-narcotic Analgesic

    14.7. Middle East & Africa Pain Management Therapeutics Market Value Share and Attractiveness Analysis, by Indication

    14.8. Middle East & Africa Pain Management Therapeutics Market Forecast, by Indication

        14.8.1. Neuropathic Pain 

        14.8.2. Fibromyalgia 

        14.8.3. Arthritic Pain 

        14.8.4. Chronic Back Pain 

        14.8.5. Migraine 

        14.8.6. Post-Operative Pain 

        14.8.7. Cancer Pain

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by Tier and Size of companies)

    15.2. Market Share / Position Analysis, by Company, 2018

    15.3. Company Profiles

        15.3.1. Pfizer Inc

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Growth Strategies

            15.3.1.3. SWOT Analysis

        15.3.2. Depomed, Inc. 

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Growth Strategies

            15.3.2.3. SWOT Analysis

        15.3.3. Endo International plc. 

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Growth Strategies

            15.3.3.3. SWOT Analysis

        15.3.4. Mankind Pharma Ltd. 

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Growth Strategies

            15.3.4.3. SWOT Analysis

        15.3.5. Merck & Co, Inc.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Growth Strategies

            15.3.5.3. SWOT Analysis

        15.3.6. Pfizer, Inc. 

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Growth Strategies

            15.3.6.3. SWOT Analysis 

        15.3.7. Teva Pharmaceutical Industries Ltd. 

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Growth Strategies

            15.3.7.3. SWOT Analysis

        15.3.8. Lupin Limited 

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Growth Strategies

            15.3.8.3. SWOT Analysis

        15.3.9. Piramal Enterprises

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Growth Strategies

            15.3.9.3. SWOT Analysis

        15.3.10. Syzygy Healthcare LLC 

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Growth Strategies

            15.3.10.3. SWOT Analysis

Choose License Type

Checkout Inquiry Sample